http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9884091-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e3a79a6fd688bbc779bcc7c3a071b57d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2278 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate | 2015-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_191e455306bf0d2bcc8a4d20672078eb |
| publicationDate | 2018-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9884091-B2 |
| titleOfInvention | Treatment of neurological diseases |
| abstract | Methods treat neurological disorders, for example neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and stroke. Particularly although not exclusively, GIP/GLP-1 co-agonist peptide is used in the treatment of such neurological disorders. Pharmaceutical compositions include a GIP/GLP-1 co-agonist peptide for use in treatment of such disorders. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11220534-B2 |
| priorityDate | 2014-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 451.